Abbott Laboratories (ABT) |
|
|
|
Abbott Laboratories Income Statement Quarterly
ABT
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
INCOME STATEMENT (Quarterly GAAP In millions $) |
(Dec 31 2020) IV. Quarter |
(Sep 30 2020) III. Quarter |
(Jun 30 2020) II. Quarter |
(Mar 31 2020) I. Quarter |
(Dec 31 2019) IV. Quarter |
Revenue From Contract With Customer Excluding Assessed Tax |
|
8,853.00 |
7,328.00 |
7,726.00 |
|
Revenue From Contract With Customer Excluding Assessed Tax |
|
- |
- |
- |
|
Total Revenue |
10,701.00 |
8,853.00 |
7,328.00 |
7,726.00 |
8,314.00 |
Cost of Goods and Services Sold |
4,493.00 |
3,966.00 |
3,263.00 |
3,281.00 |
3,434.00 |
Gross
Profit |
6,208.00 |
4,887.00 |
4,065.00 |
4,445.00 |
4,880.00 |
Selling, Administration, Marketing |
2,570.00 |
2,302.00 |
2,276.00 |
2,548.00 |
2,413.00 |
Depriciation & Amortization |
508.00 |
510.00 |
553.00 |
561.00 |
483.00 |
Research and Development Expense |
698.00 |
580.00 |
564.00 |
578.00 |
595.00 |
Restructuring charges |
- |
- |
- |
- |
- |
Other exp. /-income |
- |
- |
- |
- |
- |
Special Items |
- |
- |
- |
- |
- |
Total operating costs including COS |
8,269.00 |
7,358.00 |
6,656.00 |
6,968.00 |
6,925.00 |
Operating income/-loss
|
2,432.00 |
1,495.00 |
672.00 |
758.00 |
1,389.00 |
Other Deductions / - Income |
Interest expense |
136.00 |
137.00 |
134.00 |
139.00 |
164.00 |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
136.00 |
137.00 |
134.00 |
139.00 |
164.00 |
Extinguishment of Debt |
- |
- |
- |
- |
-63.00 |
Investment Income, Interest |
- |
- |
- |
- |
- |
Foreign Currency Transaction Gain (Loss), before Tax |
-5.00 |
-7.00 |
-1.00 |
5.00 |
2.00 |
Sale of Assets |
- |
- |
- |
- |
- |
Financing Loss/ -Income |
- |
- |
- |
- |
- |
Other loss/ -income |
-87.00 |
-56.00 |
13.00 |
-19.00 |
46.00 |
Total costs & expenses |
8,313.00 |
7,432.00 |
6,802.00 |
7,093.00 |
7,074.00 |
Income /-loss before income taxes |
2,388.00 |
1,421.00 |
526.00 |
633.00 |
1,240.00 |
Income taxes expenses/-benefit |
230.00 |
189.00 |
-11.00 |
89.00 |
191.00 |
Income after income taxes |
2,158.00 |
1,232.00 |
537.00 |
544.00 |
1,049.00 |
Net income/-loss
of other equity |
- |
- |
- |
- |
- |
Income/-loss
from cont. Ops. |
2,158.00 |
1,232.00 |
537.00 |
544.00 |
1,049.00 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
4.00 |
- |
- |
20.00 |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
2,162.00 |
1,232.00 |
537.00 |
564.00 |
1,049.00 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
2,162.00 |
1,232.00 |
537.00 |
564.00 |
1,049.00 |
EBIT |
2,524.00 |
1,558.00 |
660.00 |
772.00 |
1,404.00 |
EBITD |
2,882.00 |
1,856.00 |
932.00 |
1,039.00 |
1,677.00 |
EBITDA |
3,390.00 |
2,366.00 |
1,485.00 |
1,600.00 |
2,160.00 |
Per
Share (GAAP Quarterly, in $) |
(Dec 31 2020) IV. Quarter |
(Sep 30 2020) III. Quarter |
(Jun 30 2020) II. Quarter |
(Mar 31 2020) I. Quarter |
(Dec 31 2019) IV. Quarter |
Basic EPS (excl. extra
items) |
1.22 |
0.69 |
0.30 |
0.31 |
0.59 |
Extraordinary items |
0.00 |
0.00 |
0.00 |
0.01 |
0.00 |
Basic Net EPS |
1.22 |
0.69 |
0.30 |
0.32 |
0.59 |
Basic shares outstanding (Mill.
of Units) |
1,775.67 |
1,774.48 |
1,772.95 |
1,768.90 |
1,768.30 |
EPS other shares |
- |
- |
- |
- |
- |
Diluted Net EPS |
1.21 |
0.69 |
0.30 |
0.31 |
0.59 |
Diluted average shares (Mill.
of Units) |
1,790.53 |
1,787.85 |
1,785.04 |
1,780.58 |
1,781.84 |
Dividend per share |
0.358 |
0.357 |
0.36 |
0.358 |
0.319 |
|
|